Role of the metastasis-promoting protein osteopontin in the tumour microenvironment

Journal of Cellular and Molecular Medicine

Volumn 14, Issue 8, 2010, Pages 2037-2044

  Anborgh, Pieter H ^a   Mutrie, Jennifer C ^a,b   Tuck, Alan B ^a,b,c   Chambers, Ann F ^a,b  

^a LONDON REGIONAL CANCER PROGRAM   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Angiogenesis; Bone microenvironment; Metastasis; Osteopontin; Tumour microenvironment

Indexed keywords

INTEGRIN; OSTEOPONTIN;

ARTICLE; BIOLOGICAL MODEL; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; METASTASIS; NEOPLASM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROTEIN BINDING; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTEGRINS; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; NEOPLASMS; OSTEOPONTIN; PROTEIN BINDING; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 77957141336     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2010.01115.x     Document Type: Article

References (107)

1. Rangaswami H, Bulbule A, Kundu GC. Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol. 2006, 16:79-87.
2. Weber GF. The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta. 2001, 1552:61-85.
3. Franzen A, Heinegard D. Isolation and characterization of two sialoproteins present only in bone calcified matrix. Biochem J. 1985, 232:715-24.
4. Senger DR, Perruzzi CA, Papadopoulos A. Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation. Anticancer Res. 1989, 9:1291-9.
5. Patarca R, Freeman GJ, Singh RP. Structural and functional studies of the early T lymphocyte activation 1 (Eta-1) gene. Definition of a novel T cell-dependent response associated with genetic resistance to bacterial infection. J Exp Med. 1989, 170:145-61.
6. Rittling SR, Chambers AF. Role of osteopontin in tumour progression. Br J Cancer. 2004, 90:1877-81.
7. Tuck AB, Chambers AF, Allan AL. Osteopontin overexpression in breast cancer: knowledge gained and possible implications for clinical management. J Cell Biochem. 2007, 102:859-68.
8. Cho HJ, Cho HJ, Kim HS. Osteopontin: a multifunctional protein at the crossroads of inflammation, atherosclerosis, and vascular calcification. Curr Atheroscler Rep. 2009, 11:206-13.
9. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow. Lancet. 2001, 357:539-45.
10. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004, 4:71-8.
11. Kazanecki CC, Uzwiak DJ, Denhardt DT. Control of osteopontin signaling and function by post-translational phosphorylation and protein folding. J Cell Biochem. 2007, 102:912-24.
12. He B, Mirza M, Weber GF. An osteopontin splice variant induces anchorage independence in human breast cancer cells. Oncogene. 2006, 25:2192-202.
13. Blasberg JD, Goparaju CM, Pass HI. Lung cancer osteopontin isoforms exhibit angiogenic functional heterogeneity. J Thorac Cardiovasc Surg. 2010, 139:1587-93.
14. Christensen B, Petersen TE, Sorensen ES. Post-translational modification and proteolytic processing of urinary osteopontin. Biochem J. 2008, 411:53-61.
15. Christensen B, Kazanecki CC, Petersen TE. Cell type-specific post-translational modifications of mouse osteopontin are associated with different adhesive properties. J Biol Chem. 2007, 282:19463-72.
16. Zhang H, Hunter GK, Goldberg HA. An integrated procedure of selective injection, sample stacking and fractionation of phosphopeptides for MALDI MS analysis. Anal Chim Acta. 2007, 581:268-80.
17. Anborgh PH, Wilson SM, Tuck AB. New dual monoclonal ELISA for measuring plasma osteopontin as a biomarker associated with survival in prostate cancer: clinical validation and comparison of multiple ELISAs. Clin Chem. 2009, 55:895-903.
18. Al-Shami R, Sorensen ES, Ek-Rylander B. Phosphorylated osteopontin promotes migration of human choriocarcinoma cells via a p70 S6 kinase-dependent pathway. J Cell Biochem. 2005, 94:1218-33.
19. Xuan JW, Hota C, Chambers AF. Recombinant GST-human osteopontin fusion protein is functional in RGD-dependent cell adhesion. J Cell Biochem. 1994, 54:247-55.
20. Furger KA, Allan AL, Wilson SM. Beta(3) integrin expression increases breast carcinoma cell responsiveness to the malignancy-enhancing effects of osteopontin. Mol Cancer Res. 2003, 1:810-9.
21. Tuck AB, Hota C, Wilson SM. Osteopontin-induced migration of human mammary epithelial cells involves activation of EGF receptor and multiple signal transduction pathways. Oncogene. 2003, 22:1198-205.
22. Tuck AB, Arsenault DM, O'Malley FP. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene. 1999, 18:4237-46.
23. Tuck AB, Elliott BE, Hota C. Osteopontin-induced, integrin-dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (Met). J Cell Biochem. 2000, 78:465-75.
24. Higashikawa F, Eboshida A, Yokosaki Y. Enhanced biological activity of polymeric osteopontin. FEBS Lett. 2007, 581:2697-701.
25. Senger DR, Perruzzi CA, Papadopoulos-Sergiou A. Adhesive properties of osteopontin: regulation by a naturally occurring thrombin-cleavage in close proximity to the GRGDS cell-binding domain. Mol Biol Cell. 1994, 5:565-74.
26. Agnihotri R, Crawford HC, Haro H. Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin). J Biol Chem. 2001, 276:28261-7.
27. Takafuji V, Forgues M, Unsworth E. An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma. Oncogene. 2007, 26:6361-71.
28. Schulze EB, Hedley BD, Goodale D. The thrombin inhibitor Argatroban reduces breast cancer malignancy and metastasis via osteopontin-dependent and osteopontin-independent mechanisms. Breast Cancer Res Treat. 2008, 112:243-54.
29. Bellahcene A, Castronovo V, Ogbureke KU. Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat Rev Cancer. 2008, 8:212-26.
30. Polyak K, Haviv I, Campbell IG. Co-evolution of tumor cells and their microenvironment. Trends Genet. 2009, 25:30-8.
31. De Wever O, Demetter P, Mareel M. Stromal myofibroblasts are drivers of invasive cancer growth. Int J Cancer. 2008, 123:2229-38.
32. Li H, Fan X, Houghton J. Tumor microenvironment: the role of the tumor stroma in cancer. J Cell Biochem. 2007, 101:805-15.
33. Shevde LA, Das S, Clark DW. Osteopontin: an effector and an effect of tumor metastasis. Curr Mol Med. 2010, 10:71-81.
34. Brown LF, Papadopoulos-Sergiou A, Berse B. Osteopontin expression and distribution in human carcinomas. Am J Pathol. 1994, 145:610-23.
35. Coppola D, Szabo M, Boulware D. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res. 2004, 10:184-90.
36. Tuck AB, O'Malley FP, Singhal H. Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer. 1998, 79:502-8.
37. Forootan SS, Foster CS, Aachi VR. Prognostic significance of osteopontin expression in human prostate cancer. Int J Cancer. 2006, 118:2255-61.
38. Agrawal D, Chen T, Irby R. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst. 2002, 94:513-21.
39. Imano M, Satou T, Itoh T. Immunohistochemical expression of osteopontin in gastric cancer. J Gastrointest Surg. 2009, 13:1577-82.
40. Ye QH, Qin LX, Forgues M. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med. 2003, 9:416-23.
41. Zhang J, Takahashi K, Takahashi F. Differential osteopontin expression in lung cancer. Cancer Lett. 2001, 171:215-22.
42. Chambers AF, Wilson SM, Kerkvliet N. Osteopontin expression in lung cancer. Lung Cancer. 1996, 15:311-23.
43. Pass HI, Lott D, Lonardo F. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med. 2005, 353:1564-73.
44. Chien CY, Su CY, Chuang HC. Comprehensive study on the prognostic role of osteopontin expression in oral squamous cell carcinoma. Oral Oncol. 2009, 45:798-802.
45. Sulzbacher I, Birner P, Trieb K. Expression of osteopontin and vascular endothelial growth factor in benign and malignant bone tumors. Virchows Arch. 2002, 441:345-9.
46. Bramwell VH, Tuck AB, Wilson SM. Expression of osteopontin and HGF/met in adult soft tissue tumors. Cancer Biol Ther. 2005, 4:1336-41.
47. Saeki Y, Mima T, Ishii T. Enhanced production of osteopontin in multiple myeloma: clinical and pathogenic implications. Br J Haematol. 2003, 123:263-70.
48. Wang-Rodriguez J, Urquidi V, Rivard A. Elevated osteopontin and thrombospondin expression identifies malignant human breast carcinoma but is not indicative of metastatic status. Breast Cancer Res. 2003, 5:R136-43.
49. Gaumann A, Petrow P, Mentzel T. Osteopontin expression in primary sarcomas of the pulmonary artery. Virchows Arch. 2001, 439:668-74.
50. Chang PL, Harkins L, Hsieh YH. Osteopontin expression in normal skin and non-melanoma skin tumors. J Histochem Cytochem. 2008, 56:57-66.
51. Casson AG, Wilson SM, McCart JA. ras mutation and expression of the ras-regulated genes osteopontin and cathepsin L in human esophageal cancer. Int J Cancer. 1997, 72:739-45.
52. Weismann D, Briese J, Niemann J. Osteopontin stimulates invasion of NCI-h295 cells but is not associated with survival in adrenocortical carcinoma. J Pathol. 2009, 218:232-40.
53. Gotoh M, Sakamoto M, Kanetaka K. Overexpression of osteopontin in hepatocellular carcinoma. Pathol Int. 2002, 52:19-24.
54. Kim J, Ki SS, Lee SD. Elevated plasma osteopontin levels in patients with hepatocellular carcinoma. Am J Gastroenterol. 2006, 101:2051-9.
55. Reinholt FP, Hultenby K, Oldberg A. Osteopontin-a possible anchor of osteoclasts to bone. Proc Natl Acad Sci USA. 1990, 87:4473-5.
56. Sullivan J, Blair L, Alnajar A. Expression of a prometastatic splice variant of osteopontin, OPNC, in human pancreatic ductal adenocarcinoma. Surgery. 2009, 146:232-40.
57. Finak G, Bertos N, Pepin F. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med. 2008, 14:518-27.
58. Rittling SR, Chen Y, Feng F. Tumor-derived osteopontin is soluble, not matrix associated. J Biol Chem. 2002, 277:9175-82.
59. Kubota T, Zhang Q, Wrana JL. Multiple forms of SppI (secreted phosphoprotein, osteopontin) synthesized by normal and transformed rat bone cell populations: regulation by TGF-beta. Biochem Biophys Res Commun. 1989, 162:1453-9.
60. Schwertfeger KL, Xian W, Kaplan AM. A critical role for the inflammatory response in a mouse model of preneoplastic progression. Cancer Res. 2006, 66:5676-85.
61. Wai PY, Guo L, Gao C. Osteopontin inhibits macrophage nitric oxide synthesis to enhance tumor proliferation. Surgery. 2006, 140:132-40.
62. Feng B, Rollo EE, Denhardt DT. Osteopontin (OPN) may facilitate metastasis by protecting cells from macrophage NO-mediated cytotoxicity: evidence from cell lines down-regulated for OPN expression by a targeted ribozyme. Clin Exp Metastasis. 1995, 13:453-62.
63. Denhardt DT, Chambers AF. Overcoming obstacles to metastasis-defenses against host defenses: osteopontin (OPN) as a shield against attack by cytotoxic host cells. J Cell Biochem. 1994, 56:48-51.
64. Crawford HC, Matrisian LM, Liaw L. Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo. Cancer Res. 1998, 58:5206-15.
65. Patsialou A, Wyckoff J, Wang Y. Invasion of human breast cancer cells in vivo requires both paracrine and autocrine loops involving the colony-stimulating factor-1 receptor. Cancer Res. 2009, 69:9498-506.
66. Shih J, Yuan A, Chen JJ, Yang P. Tumor-associated macrophage: its role in cancer invasion and metastasis. J Cancer Mol. 2006, 2:101-6.
67. Diao H, Iwabuchi K, Li L. Osteopontin regulates development and function of invariant natural killer T cells. Proc Natl Acad Sci USA. 2008, 105:15884-9.
68. Larkin J, Renukaradhya GJ, Sriram V. CD44 differentially activates mouse NK T cells and conventional T cells. J Immunol. 2006, 177:268-79.
69. Terabe M, Berzofsky JA. NKT cells in immunoregulation of tumor immunity: a new immunoregulatory axis. Trends Immunol. 2007, 28:491-6.
70. Bostrom K. Osteopontin, a missing link in PDGF-induced smooth muscle cell migration. Cardiovasc Res. 2007, 75:634-5.
71. Lu C, Bonome T, Li Y. Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res. 2007, 67:1757-68.
72. Du XL, Jiang T, Zhao WB. Gene alterations in tumor-associated endothelial cells from endometrial cancer. Int J Mol Med. 2008, 22:619-32.
73. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996, 86:353-64.
74. Chakraborty G, Jain S, Kundu GC. Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res. 2008, 68:152-61.
75. Shijubo N, Uede T, Kon S. Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma. Am J Respir Crit Care Med. 1999, 160:1269-73.
76. Shijubo N, Uede T, Kon S. Vascular endothelial growth factor and osteopontin in tumor biology. Crit Rev Oncog. 2000, 11:135-46.
77. Takahashi F, Akutagawa S, Fukumoto H. Osteopontin induces angiogenesis of murine neuroblastoma cells in mice. Int J Cancer. 2002, 98:707-12.
78. Dai J, Peng L, Fan K. Osteopontin induces angiogenesis through activation of PI3K/AKT and ERK1/2 in endothelial cells. Oncogene. 2009, 28:3412-22.
79. Leali D, Dell'Era P, Stabile H. Osteopontin (Eta-1) and fibroblast growth factor-2 cross-talk in angiogenesis. J Immunol. 2003, 171:1085-93.
80. McAllister SS, Gifford AM, Greiner AL. Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell. 2008, 133:994-1005.
81. Bellahcene A, Castronovo V. Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. Am J Pathol. 1995, 146:95-100.
82. Oyama T, Sano T, Hikino T. Microcalcifications of breast cancer and atypical cystic lobules associated with infiltration of foam cells expressing osteopontin. Virchows Arch. 2002, 440:267-73.
83. Wang X, Chao L, Ma G. Primary breast carcinoma: association of mammographic calcifications with osteopontin expression. Radiology. 2010, 254:69-78.
84. Hirota S, Nakajima Y, Yoshimine T. Expression of bone-related protein messenger RNA in human meningiomas: possible involvement of osteopontin in development of psammoma bodies. J Neuropathol Exp Neurol. 1995, 54:698-703.
85. Maki M, Hirota S, Kaneko Y. Expression of osteopontin messenger RNA by macrophages in ovarian serous papillary cystadenocarcinoma: a possible association with calcification of psammoma bodies. Pathol Int. 2000, 50:531-5.
86. Bai Y, Zhou G, Nakamura M. Survival impact of psammoma body, stromal calcification, and bone formation in papillary thyroid carcinoma. Mod Pathol. 2009, 22:887-94.
87. Kuroda N, Hamaguchi N, Ohara M. Large cell neuroendocrine carcinoma of the lung with calcification and expression of osteopontin. Med Mol Morphol. 2007, 40:218-20.
88. Modolo F, Biz MT, Martins MT. Expression of extracellular matrix proteins in adenomatoid odontogenic tumor. J Oral Pathol Med. 2010, 39:230-5.
89. Cheng J, Huo DH, Kuang DM. Human macrophages promote the motility and invasiveness of osteopontin-knockdown tumor cells. Cancer Res. 2007, 67:5141-7.
90. Bourassa B, Monaghan S, Rittling SR. Impaired anti-tumor cytotoxicity of macrophages from osteopontin-deficient mice. Cell Immunol. 2004, 227:1-11.
91. Kaarteenaho R, Sormunen R, Paakko P. Variable expression of tenascin-C, osteopontin and fibronectin in inflammatory myofibroblastic tumour of the lung. APMIS. 2010, 118:91-100.
92. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006, 6:392-401.
93. Pereira RO, Carvalho SN, Stumbo AC. Osteopontin expression in coculture of differentiating rat fetal skeletal fibroblasts and myoblasts. In Vitro Cell Dev Biol Anim. 2006, 42:4-7.
94. Lenga Y, Koh A, Perera AS. Osteopontin expression is required for myofibroblast differentiation. Circ Res. 2008, 102:319-27.
95. Pazolli E, Luo X, Brehm S. Senescent stromal-derived osteopontin promotes preneoplastic cell growth. Cancer Res. 2009, 69:1230-9.
96. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature. 2004, 432:332-7.
97. Anderberg C, Li H, Fredriksson L. Paracrine signaling by platelet-derived growth factor-CC promotes tumor growth by recruitment of cancer-associated fibroblasts. Cancer Res. 2009, 69:369-78.
98. Allan AL, George R, Vantyghem SA. Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer. Am J Pathol. 2006, 169:233-46.
99. Nemoto H, Rittling SR, Yoshitake H. Osteopontin deficiency reduces experimental tumor cell metastasis to bone and soft tissues. J Bone Miner Res. 2001, 16:652-9.
100. Heinegard D, Andersson G, Reinholt FP. Roles of osteopontin in bone remodeling. Ann NY Acad Sci. 1995, 760:213-22.
101. Ibrahim T, Leong I, Sanchez-Sweatman O. Expression of bone sialoprotein and osteopontin in breast cancer bone metastases. Clin Exp Metastasis. 2000, 18:253-60.
102. Kang Y, Siegel PM, Shu W. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 2003, 3:537-49.
103. Carlinfante G, Vassiliou D, Svensson O. Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma. Clin Exp Metastasis. 2003, 20:437-44.
104. Chellaiah MA, Kizer N, Biswas R. Osteopontin deficiency produces osteoclast dysfunction due to reduced CD44 surface expression. Mol Biol Cell. 2003, 14:173-89.
105. Yoneda T. Arterial microvascularization and breast cancer colonization in bone. Histol Histopathol. 1997, 12:1145-9.
106. Cook AC, Chambers AF, Turley EA. Osteopontin induction of hyaluronan synthase 2 expression promotes breast cancer malignancy. J Biol Chem. 2006, 281:24381-9.
107. Wang J, Levenson AS, Satcher RL. Identification of a unique set of genes altered during cell-cell contact in an in vitro model of prostate cancer bone metastasis. Int J Mol Med. 2006, 17:849-56.